Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 03/16/2023 | 125.99% | JP Morgan | $12 → $8 | Maintains | Neutral |
| 01/27/2023 | 69.49% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 01/24/2023 | 12.99% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 97.74% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 125.99% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 154.24% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 182.49% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 97.74% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 210.73% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 464.97% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 351.98% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1453.67% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1594.92% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 945.2% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 888.7% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 2216.38% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1764.41% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1171.19% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1284.18% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/10/2023 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 03/16/2023 | 125.99% | 摩根大通 | 12 美元 → 8 美元 | 維護 | 中立 |
| 01/27/2023 | 69.49% | SVB Leerink | 8 美元 → 6 美元 | 維護 | 市場表現 |
| 01/24/2023 | 12.99% | 摩根士丹利 | 7 美元 → 4 美元 | 維護 | 體重不足 |
| 08/15/2022 | 97.74% | 摩根士丹利 | 6 美元 → 7 美元 | 維護 | 體重不足 |
| 03/02/2022 | 125.99% | 摩根大通 | 10 美元 → 8 美元 | 維護 | 中立 |
| 03/01/2022 | 154.24% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 市場表現 |
| 2022 年 2 月 16 日 | 182.49% | SVB Leerink | 11 美元 → 10 美元 | 維護 | 市場表現 |
| 01/06/2022 | 97.74% | 摩根士丹利 | 14 美元 → 7 美元 | 降級 | 等重 → 減重 |
| 11/18/2021 | 210.73% | SVB Leerink | → 11 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 2021 年 10 月 20 日 | 464.97% | SVB Leerink | 60 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 2021 年 10 月 20 日 | 351.98% | 摩根大通 | 61 美元 → 16 美元 | 降級 | 超重 → 中性 |
| 2021 年 5 月 10 日 | 1453.67% | 摩根士丹利 | → 55 美元 | 降級 | 超重 → 重量相等 |
| 2021 年 9 月 9 日 | 1594.92% | SVB Leerink | → 60 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 8 月 18 日 | 945.2% | 摩根士丹利 | 35 美元 → 37 美元 | 維護 | 超重 |
| 06/03/2021 | 888.7% | 摩根士丹利 | 82 美元 → 35 美元 | 維護 | 超重 |
| 04/06/2021 | 2216.38% | 摩根士丹利 | 49 美元 → 82 美元 | 維護 | 超重 |
| 2021 年 1 月 29 日 | 1764.41% | 摩根大通 | 45 美元 → 66 美元 | 維護 | 超重 |
| 11/25/2020 | — | Evercore ISI 集團 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 11/24/2020 | 1171.19% | 摩根大通 | → 45 美元 | 啓動覆蓋開啓 | → 超重 |
| 11/24/2020 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 11/24/2020 | 1284.18% | 摩根士丹利 | → 49 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的目標價格是多少？
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
摩根大通於2023年8月10日公佈了Atea Pharmicals（納斯達克股票代碼：AVIR）的最新目標股價。這家分析公司將目標股價定爲0.00美元，預計AVIR將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的最新分析師評級是多少？
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.
Atea Pharmicals（納斯達克股票代碼：AVIR）的最新分析師評級由摩根大通提供，Atea Pharmicals下調了其減持評級。
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Atea Pharmicals的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Atea Pharmicals的最新評級是在2023年8月10日提交的，因此您應該預計下一個評級將在2024年8月10日左右公佈。
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析師對Atea Pharmicals（AVIR）的評級是否正確？
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Atea Pharmicals（AVIR）評級被下調，目標股價爲0.00美元至0.00美元。Atea Pharmicals（AVIR）目前的交易價格爲3.54美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。
